On April 2, 2026, Lisata Therapeutics, Inc. (the "Company" or "Lisata") announced an extension of the deadline for the tender offer for its outstanding shares of common stock. This decision comes as part of the previously announced Agreement and Plan of Merger dated March 6, 2026, between Lisata and Kuva Labs Inc. The new deadline for the tender offer has been pushed from April 3, 2026, to April 13, 2026, allowing additional time for shareholders to consider the offer. This extension is seen as a strategic move to ensure that all shareholders have adequate time to evaluate the terms of the merger and make informed decisions regarding their investments. The waiver to the Merger Agreement related to this extension has been documented and is available as Exhibit 99.1 in the current report on Form 8-K. The Company believes that this extension will facilitate a smoother transition and enhance shareholder engagement during this critical period. Investors are encouraged to review the details of the merger agreement and the implications of this extension on their holdings. The Company remains committed to providing transparent communication and ensuring that all stakeholders are informed throughout the merger process.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.